Innoveren Scientific (IVRN) 10-Q 14 Nov 18 2018 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2018	Nov. 12, 2018
Document And Entity Information
Entity Registrant Name	Medovex Corp.
Entity Central Index Key	1,591,165
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Common Stock, Shares Outstanding		24,717,271
Trading Symbol	MDVX
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2,018

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Current Assets
Cash	$ 227,960	$ 245,026
Accounts receivable	141,290	157,069
Other receivables	9,537	86,888
Inventory	206,495	294,714
Prepaid expenses	59,068	204,532
Short-term receivable		150,000
Total Current Assets	644,350	1,138,229
Property and Equipment, net of accumulated depreciation	66,551	87,173
Deposits	2,751	2,751
Total Assets	713,652	1,228,153
Current Liabilities
Interest payable	80,709	69,222
Accounts payable	688,958	196,171
Accounts payable to related parties	69,503	12,319
Accrued payroll	124,817
Accrued liabilities	243,435	64,000
Notes payable, current portion	54,363	132,294
Short-term note payable, net of debt discount	533,128
Dividend payable	19,271
Unearned revenue		1,048
Total Current Liabilities	1,814,184	475,054
Long-Term Liabilities
Notes payable, net of current portion		38,990
Deferred rent	67	688
Total Long-Term Liabilities	67	39,678
Total Liabilities	1,814,251	514,732
Stockholders' (Deficit) Equity
Common stock - $.001 par value: 49,500,000 shares authorized, 23,473,314 and 21,163,013 shares issued at September 30, 2018 (unaudited) and December 31, 2017, respectively, 23,548,304 and 21,163,013 shares outstanding at September 30, 2018 and December 31, 2017, respectively	23,548	21,163
Additional paid-in capital	35,205,227	33,509,648
Accumulated deficit	(36,329,383)	(32,817,403)
Total Stockholders' (Deficit) Equity	(1,100,599)	713,421
Total Liabilities and Stockholders' (Deficit) Equity	713,652	1,228,153
Series A Preferred Stock [Member]
Stockholders' (Deficit) Equity
Preferred stock value		13
Total Stockholders' (Deficit) Equity		13
Series B Preferred Stock [Member]
Stockholders' (Deficit) Equity
Preferred stock value	9
Total Stockholders' (Deficit) Equity	$ 9

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2018	Dec. 31, 2017
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	49,500,000	49,500,000
Common stock, shares issued	23,473,314	21,163,013
Common stock, shares outstanding	23,473,314	21,163,013
Series A Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	45,000	45,000
Preferred stock, shares issued		12,740
Preferred stock, shares outstanding		12,740
Series B Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000	10,000
Preferred stock, shares issued	9,250
Preferred stock, shares outstanding	9,250

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Income Statement [Abstract]
Revenues	$ 208,713	$ 117,277	$ 605,058	$ 117,277
Less: Discounts Allowed	(2,554)		(6,285)
Cost of Goods Sold	(122,436)	(96,683)	(425,399)	(96,683)
Gross Profit	83,723	20,594	173,374	20,594
Operating Expenses
General and administrative	943,988	1,092,084	2,708,273	3,540,500
Sales and marketing	215,039	216,950	666,092	444,708
Research and development	46,219	70,151	201,529	461,924
Depreciation	6,728	7,109	20,622	20,000
Total Operating Expenses	1,211,974	1,386,294	3,596,516	4,467,132
Operating Loss	(1,128,251)	(1,365,700)	(3,423,142)	(4,446,538)
Other Expenses
Foreign currency transaction loss	3,849		15,881
Interest expense	40,197	1,654	72,957	393,890
Total Other Expenses	44,046	1,654	88,838	393,890
Total Loss from Continuing Operations	(1,172,297)	(1,367,354)	(3,511,980)	(4,840,428)
Discontinued Operations
Loss from discontinued operations				1,163
Total Loss from Discontinued Operations				(1,163)
Net Loss	(1,172,297)	(1,367,354)	(3,511,980)	(4,841,591)
Dividend on outstanding Series B Preferred stock	(11,563)		(19,271)
Deemed dividend on beneficial conversion features			(259,350)
Net loss attributable to common shareholders	$ (1,183,860)	$ (1,367,354)	$ (3,790,601)	$ (4,841,591)
Loss per share - Basic:
Continuing Operations	$ (0.05)	$ (0.07)	$ (0.16)	$ (0.26)
Discontinued Operations
Net Loss per share	(0.05)	(0.07)	(0.16)	(0.26)
Loss per share - Diluted:
Continuing Operations	(0.05)	(0.07)	(0.17)	(0.26)
Discontinued Operations
Net Loss per share	$ (0.05)	$ (0.07)	$ (0.17)	$ (0.26)
Weighted average outstanding shares used to compute basic net loss per share	23,473,314	20,504,932	22,786,208	18,332,398
Weighted average outstanding shares used to compute diluted net loss per share	23,473,314	20,504,932	22,786,208	18,332,398

Consolidated Statement of Stock

Consolidated Statement of Stockholders' (Deficit) Equity (Unaudited) - 9 months ended Sep. 30, 2018 - USD ($)	Series A Preferred Stock [Member]	Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Beginning Balance at Dec. 31, 2017	$ 13		$ 21,163	$ 33,509,648	$ (32,817,403)	$ 713,421
Beginning Balance, Shares at Dec. 31, 2017	12,740		21,163,013
Issuance of common stock pursuant to a private placement completed in February 2018, net of offering costs			$ 770	241,727		242,497
Issuance of common stock pursuant to a private placement completed in February 2018, net of offering costs, shares			770,000
Issuance of warrants pursuant to a private placement completed in February 2018				52,003		52,003
Issuance of warrants in connection with short-term debt in March 2018				25,646		25,646
Issuance of common stock pursuant to preferred stock conversion in March 2018	$ (13)		$ 1,274	(1,261)
Issuance of common stock pursuant to preferred stock conversion in March 2018, shares	(12,740)		1,274,000
Issuance of common stock pursuant to conversion of convertible debt in April 2018			$ 266	100,928		101,194
Issuance of common stock pursuant to conversion of convertible debt in April 2018, shares			266,301
Issuance of preferred stock pursuant to a private placement completed in May 2018, net of offering costs		$ 8		413,174		413,182
Issuance of preferred stock pursuant to a private placement completed in May 2018, net of offering costs, shares		8,250
Issuance of warrants pursuant to a private placement completed in May 2018				161,206		161,206
Convertible preferred stock - beneficial conversion feature pursuant to a private placement completed in May 2018				245,612		245,612
Issuance of preferred stock pursuant to conversion of short-term debt in May 2018		$ 1		68,773		68,774
Issuance of preferred stock pursuant to conversion of short-term debt in May 2018, shares		1,000
Issuance of warrants pursuant to conversion of short-term debt in May 2018				17,488		17,488
Convertible preferred stock - beneficial conversion feature pursuant to conversion of short-term debt in May 2018				13,738		13,738
Issuance of common stock in exchange for Consulting services in August 2018			$ 75	23,925		24,000
Issuance of common stock in exchange for Consulting services in August 2018, shares			74,990
Issuance of warrants in connection with short-term debt in August 2018				192,330		192,330
Issuance of warrants in connection with short-term debt in September 2018				52,246		52,246
Dividend payable				(19,271)		(19,271)
Stock based compensation				107,315		107,315
Net loss					(3,511,980)	(3,511,980)
Ending Balance at Sep. 30, 2018		$ 9	$ 23,548	$ 35,205,227	$ (36,329,383)	$ (1,100,599)
Ending Balance, shares at Sep. 30, 2018		9,250	23,548,304

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Cash Flows from Operating Activities
Net loss	$ (3,511,980)	$ (4,841,591)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	20,622	20,000
Amortization of debt discount	53,353	31,772
Debt conversion expense		355,985
Stock-based compensation	107,315	611,522
Non-cash consulting services	24,000
Straight-line rent adjustment	(621)	(196)
Changes in operating assets and liabilities, net of effects of disposition:
Accounts receivable	15,779	(94,779)
Other receivables	77,351	(23,369)
Prepaid expenses	145,464	224,416
Inventory	88,219	(164,867)
Accounts payable	492,787	43,106
Accounts payable to related parties	57,184	671
Interest payable	11,487
Unearned revenue	(1,048)
Accrued payroll	124,817
Accrued liabilities	179,435	(84,800)
Net Cash Used in Operating Activities	(2,115,836)	(3,922,130)
Cash Flows from Investing Activities
Payment received from Streamline note receivable	150,000
Expenditures for property and equipment		(14,808)
Net Cash Provided by (Used in) Investing Activities	150,000	(14,808)
Cash Flows from Financing Activities
Principal payments under note payable obligations	(215,730)	(112,342)
Proceeds from issuance of common stock and preferred stock, net of offering costs	901,291	3,838,671
Proceeds from issuance of warrants, net of offering costs	238,855	1,248,575
Proceeds from issuance of convertible debt	74,354
Proceeds from issuance of short term loan	950,000
Net Cash Provided by Financing Activities	1,948,770	4,974,904
Net Increase/(Decrease) in Cash	(17,066)	1,037,966
Cash - Beginning of period	245,026	892,814
Cash - End of period	227,960	1,930,780
Supplementary Cash Flow Information
Cash paid for interest	4,768	6,130
Non-cash investing and financing activities
Financing agreement for insurance policy	74,672	66,895
Conversion of convertible note and accrued interest to common stock	101,194	718,079
Conversion of short-term loan to common stock		126,720
Conversion of short-term loan to preferred stock and warrants	100,000
Issuance of warrants for conversion of notes		305,201
Common stock issued for board fees		240,000
Issuance of common stock for preferred stock conversion	1,274	931
Issuance of common stock warrants for placement agent fees		304,183
Issuance of common stock for consideration of cancellation of warrants		208,000
Issuance of warrants for promissory note	25,646
Dividends accrued	19,271
Issuance of warrants for Bridge Loan	$ 244,576

Description of the Company

Description of the Company	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Description of the Company	Note 1 - Description of the Company MedoveX Corp. (the “Company” or “MedoveX”) was incorporated in Nevada on July 30, 2013 as SpineZ Corp. (“SpineZ”) and changed its name to MedoveX Corp. on March 20, 2014. MedoveX is the parent company of Debride Inc. (“Debride”), which was incorporated under the laws of the State of Florida on October 1, 2012. The Company is in the business of designing and marketing proprietary medical devices for commercial use in the United States and Europe. The Company received CE marking in June 2017 for the DenerveX System and it is now commercially available throughout the European Union and several other countries that accept CE marking. The Company’s first sale of the DenerveX System occurred in July 2017. The Company plans to seek approval for the DenerveX System from the Food & Drug Administration (“FDA”) in the United States.

Basis of Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Basis of Presentation	Note 2 – Basis of presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“GAAP”) and with the rules and regulations of the Securities and Exchange Commission (“SEC”) that permit reduced disclosure for interim periods. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments which included only normal recurring adjustments, necessary to present fairly the Company’s financial position as of September 30, 2018 and the results of operations for the three and nine months ended September 30, 2018 and 2017, and cash flows for the nine months ended September 30, 2018 and 2017. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto for the fiscal year ended December 31, 2017, included in the Company’s Annual Report on Form 10-K. The results for the three and nine months ended September 30, 2018 are not necessarily indicative of the results to be expected for the year ending December 31, 2018 or for any other interim period or for any future year. principles of consolidation These unaudited condensed consolidated financial statements that present the Company’s results of operations for the three and nine months ended September 30, 2018 and 2017, and cash flows for the nine months ended September 30, 2018 and 2017, include Debride and the accounts of the Company as well as its formerly wholly-owned subsidiary, Streamline Inc. (“Streamline”). All intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates In preparing the financial statements, U.S. GAAP requires disclosure regarding estimates and assumptions used by management that affect the amounts reported in financial statements and accompanying notes. The Company’s significant estimates include the deferred income tax asset and the related valuation allowance, and the fair value of its share-based payment arrangements. For those estimates that are sensitive to the outcome of future events, actual results could differ from those estimates. Change in Accounting Estimates The Company had three years of historical stock price information available as of September 30, 2018. As such, only the Company’s historical information was solely used in calculating annualized volatility utilized in the Black-Sholes valuation method in determining the fair value of warrants issued. In prior periods, annualized volatility was calculated using the historical price of the Company’s stock price information in addition to three comparative companies in an active market. Foreign Currency The Company’s revenues and expenses transacted in foreign currencies are recorded as they occur at exchange rates in effect at the time of each transaction. Realized gains and losses on foreign currency transactions are recorded as a component of other income or expense, net on the Company’s consolidated statements of operations. The Company recorded approximately $4,000 and $5,600, respectively, in foreign currency transaction expense for the three and nine months ended September 30, 2018. The Company did not incur any foreign currency transaction costs related to revenues and expenses transacted in foreign currencies for the three and nine months ending September 30, 2017. Foreign currency denominated monetary assets and liabilities of the Company are measured at the end of each reporting period using the exchange rate as of the balance sheet date and are recorded as a component of other income or expense, net on the Company’s consolidated statements of operations. As of September 30, 2018, the Company recorded a net translation loss of approximately $10,200 in foreign currency denominated monetary assets and liabilities. The Company did not incur any foreign currency translation costs related to foreign currency denominated monetary assets and liabilities for the three and nine months ending September 30, 2017. Recently Issued Accounting Pronouncements The Company considers the applicability and impact of all ASUs issued, both effective and not yet effective. In May 2014, the FASB issued ASU 2014-09, “Revenue Recognition - Revenue from Contracts with Customers” (ASU 2014-09) that requires companies to recognize revenue when a customer obtains control rather than when companies have transferred substantially all risks and rewards of a good or service. This update is effective for annual reporting periods beginning on or after December 15, 2017 and interim periods therein and requires expanded disclosures. The adoption of this standard did not have a material impact on the consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases. ASU 2016-02 is effective for public companies for annual reporting periods beginning after December 15, 2018, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. The Company is currently assessing the impact the adoption of ASU 2016-02 will have on its consolidated financial statements. In July 2017, FASB issued ASU No. 2017-11 to provide new guidance for classification and accounting of financial instruments with down round features. The update requires entities to recognize the effect of a down round feature in a freestanding equity-classified financial instrument only when it is triggered. The effect of triggering such a feature should be recognized as a dividend and a reduction to income available to common shareholders in calculating basic EPS. ASU 2017-11 is effective for public companies for annual reporting periods beginning after December 15, 2018, including interim periods therein. The Company adopted the amendments of ASU 2017-11 effective January 1, 2018.

Accounts Receivable

Accounts Receivable	9 Months Ended
	Sep. 30, 2018
Receivables [Abstract]
Accounts Receivable	Note 3 – Accounts Receivable Accounts receivable primarily represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables.

Other Receivables

Other Receivables	9 Months Ended
	Sep. 30, 2018
Receivables [Abstract]
Other Receivables	Note 4 – Other Receivables Other receivables include input and importation value added tax (VAT) paid by the Company for conducting business in the European Union (“EU”) and for importing goods from outside the EU.

Inventory

Inventory	9 Months Ended
	Sep. 30, 2018
Inventory Disclosure [Abstract]
Inventory	Note 5 – Inventory Inventory consists only of finished goods and are valued at the lower of cost or net realizable value, using the first-in, first-out (FIFO) method. Inventories consisted of the following items as of September 30, 2018, and December 31, 2017: September 30, 2018 December 31, 2017 Split Return Electrodes $ — $ 1,868 Denervex device 71,495 111,596 Pro-40 generator 135,000 181,250 Total $ 206,495 $ 294,714

Property and Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2018
Property, Plant and Equipment [Abstract]
Property and Equipment	Note 6 - Property and Equipment Property and equipment, net, consists of the following: Useful Life September 30, 2018 December 31, 2017 Furniture and fixtures 5 years $ 67,777 $ 67,777 Computers and software 3 years 31,738 31,738 Leasehold improvements 5 years 35,676 35,676 135,191 135,191 Less accumulated depreciation (68,640 ) (48,018 ) Total $ 66,551 $ 87,173 Depreciation expense amounted to $6,728 and $20,622, respectively, for the three and nine months ended September 30, 2018. Depreciation expense amounted to $7,109 and $20,000, respectively, for the three and nine months ended September 30, 2017.

Equity Transactions

Equity Transactions	9 Months Ended
	Sep. 30, 2018
Equity [Abstract]
Equity Transactions	Note 7 - Equity Transactions Common Stock Issuance In November 2016, the Board authorized the issuance of shares of common stock to all Board members, both current and former, in an amount equivalent to $240,000, representing their accrued but unpaid directors’ fees as of December 31, 2016. In January 2017, the Company issued an aggregate of 173,911 shares at $1.38 per share, which was the average closing price of the Company’s stock during 2016, to fulfill this obligation. The closing price of the Company’s stock on January 17, 2017, the day the shares were issued, was $1.16 per share. In August 2017, the Board authorized the issuance of 125,000 shares of common stock to a certain member of the Board of Directors and 175,000 shares of common stock to a certain consultant. At the inception of the agreement, 25% of the shares were issued to both the director and the consultant. In December 2017, 50,000 shares were issued to the consultant. As of September 30, 2018, the board member and consultant are due to be issued an additional 75,000 shares. The 75,000 shares were valued at the performance completion date, August 16, 2018, at $0.32 per share, which was the closing price on that date. As the shares had not been issued as of September 30, 2018, the fair value of the liability at the performance completion date $24,000 is in accrued liabilities. The Company does not expect to issue any remaining shares as the board member and the consultant are no longer associated with the Company. Stock-Based Compensation Plan 2013 Stock Option Incentive Plan We utilize the Black-Scholes valuation method to recognize stock-based compensation expense over the vesting period. The expected life represents the period that our stock-based compensation awards are expected to be outstanding. For the three and nine months ended September 30, 2018, the Company recognized approximately $22,000 and $107,000, respectively, as compensation expense with respect to vested stock options. For the three and nine months ended September 30, 2017, the Company recognized approximately $111,000 and $612,000, respectively, as compensation expense with respect to vested stock options. Stock Option Activity As of September 30, 2018, there were 142,825 shares of time-based, non-vested stock options outstanding. As of September 30, 2018, there was approximately $53,000 of total unrecognized stock-based compensation related to these non-vested stock options. That expense is expected to be recognized on a straight-line basis over a weighted average period of 1.39 years. The following is a summary of stock option activity at September 30, 2018: Shares Weighted Average Exercise Price Weighted Average Remaining Term (Years) Outstanding at 12/31/2017 1,314,059 $ 2.01 8.19 Forfeited (136,035 ) $ 1.69 — Outstanding at 9/30/2018 1,178,024 $ 2.04 7.45 Exercisable at 9/30/2018 1,035,200 $ 2.16 7.37 Private Placement On February 26, 2018, the Company entered into a securities purchase agreement with selected accredited investors whereby the Company sold an aggregate of 770,000 shares of common stock and 385,000 warrants to purchase common stock. The offering resulted in $308,000 in gross proceeds to the Company. The warrants have a five-year term commencing six months from issuance with an exercise price of $0.75. The Company allocated $52,003 to the warrants and the remainder to the issuance of the common stock. The Company incurred $13,500 in legal expenses related to the offering. On May 1, 2018, the Company entered into a securities purchase agreement with selected accredited investors whereby the Company offered up to $1,000,000 in units. Each unit had a purchase price of $100,000 and consisted of (i) 1,000 shares of the Company’s 5% Series B Convertible Preferred Stock (the “ Series B Shares As a result of the offering, the Company sold an aggregate of 8.25 Units and issued to the Investors an aggregate of 8,250 Series B Shares and 2,062,500 warrants to purchase common stock, resulting in total $825,000 gross proceeds to the Company. The Company incurred $5,000 in legal fees related to the offering, which resulted in $820,000 net cash received from the offering. The 8,250 Series B Shares sold in the Offering are initially convertible into an aggregate of 2,062,500 shares of Common Stock. The net proceeds of the offering of $820,000 were first allocated to the warrants issued to investors, and the Series B Shares based on their relative fair value. The Company recognized a beneficial conversion feature related to the Series B Shares of approximately $246,000, which was credited to additional paid-in capital. Because the Series B Shares can immediately be converted by the holder, the discount recognized by the allocation of proceeds to the beneficial conversion feature was immediately accreted and recognized as a dividend to the preferred shareholders. On August 1, 2018 the annual dividend rate on the Series B Shares was adjusted to 12%, which is equal to the same rate as the convertible debt issued in August and September 2018, pursuant to an adjustment provision in the Series B Shares which entitles the holders to receive a more beneficial annual dividend rate offered in any subsequent financings. The Company had accrued unpaid dividends in the amount of approximately $30,000 as of September 30, 2018, related to the Series B Shares. On August 8, 2018, the Company completed the issuance of convertible debt at an initial conversion price of $0.40. Accordingly the exercise price on all of the warrants issued with the Series B Shares were adjusted downward to $0.40. In conjunction with the downward adjustment, the Company recorded a deemed dividend of approximately $108,000 representing the difference in the fair value of the warrants immediately before and after the adjustment to the exercise price. preferred Stock Conversion On March 30, 2018, 12,740 shares of Series A Preferred Stock were converted into an aggregate of 1,274,000 restricted shares of authorized common stock, par value $0.001 per share. Convertible Notes In August and September 2018, the Company entered into a securities purchase agreement with select accredited investors, whereby the Company offered up to $1,000,000 in units at a purchase price of $50,000 per unit. Each Unit consists of (i) a 12% senior secured convertible note, initially convertible into shares of the Company’s common stock, par value $0.001 per share, at a conversion price equal to the lesser of $0.40 or ninety percent (90%) of the per share purchase price of any shares of common stock or common stock equivalents issued in future private placements of equity and/or debt securities completed by the Company following this offering, and (ii) a three-year warrant to purchase such number of shares of the Company’s common stock equal to one hundred percent (100%) of the number of shares of common stock issuable upon conversion of the notes at $0.40. The Warrants are exercisable at a price equal to the lesser of $0.75 or ninety percent (90%) of the per share purchase price of any shares of common stock or common stock equivalents issued in future private placements of the debt and/or equity securities completed by the Company following the issuance of warrants. The notes are secured by all of the assets of the Company. ASU 2017-11 provided that when determining whether certain financial instruments should be classified as liability or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. If a down round feature on the conversion option embedded in the note is triggered, the Company will evaluate whether a beneficial conversion feature exists, the Company will record the amount as a debt discount and will amortize it over the remaining term of the debt. If the down round feature in the warrants is triggered, the Company will recognize the effect of the down found as a deemed dividend which will reduce the income available to common stockholders. In the offering, the Company sold an aggregate of 15 units and issued to investors an aggregate of $750,000 in principal amount of convertible notes and 1,875,000 warrants to purchase common stock, resulting in total gross proceeds of $750,000 to the Company. If converted at $0.40 the convertible notes sold in the offering are convertible into an aggregate of 1,875,000 shares of common stock. The Company recorded the proceeds from the notes and the accompanying warrants, which accrete over the period the notes are outstanding, on a relative fair value basis of approximately $505,000 and $245,000, respectively. Accretion expense for the three and nine month period ending September 30, 2018 related to these convertible notes was approximately $28,400. The Company recognized $10,700 in unpaid accrued interest expense related to the notes as of September 30, 2018. Debt Conversion Convertible Debenture On April 26, 2018, the Company’s $100,000 5% convertible debenture and unpaid accrued interest was converted into an aggregate of 266,301 shares of common stock, eliminating the Company’s debt obligation. The debt was converted into shares at $0.38 per share, which was 85% of the average closing price of the Company’s stock during the twenty trading days immediately preceding the delivery of the notice of conversion. The market value of the common stock on the date of the conversion was $0.40. This difference noted above lead to an immaterial amount related to a beneficial conversion feature. Promissory Note On May 15, 2018, the Company entered into a modification agreement with Steve Gorlin whereby he agreed to convert $100,000 of the $200,000 outstanding promissory note into Series B Shares. The conversion of $100,000 was converted under the terms of the May 1, 2018 securities purchase agreement. The $100,000 conversion was converted into an aggregate of 1,000 shares of the Company’s Series B Shares and 250,000 warrants to purchase common stock, eliminating $100,000 of the Company’s $200,000 debt obligation. The converted $100,000 was first allocated to the fair value of the warrants issued in conjunction with the conversion, and the Series B Shares based on their relative fair value. The Company recognized a beneficial conversion feature related to the Series B Shares of approximately $14,000, which was credited to additional paid-in capital. Because the Series B Shares can immediately be converted by the holder, the discount recognized by the allocation of proceeds to the beneficial conversion feature was immediately accreted and recognized as a dividend to the preferred shareholders. On August 21, 2018, the Company paid back the remaining $100,000 plus unpaid accrued interest in the amount of $2,944, eliminating the Company’s debt obligation.

Commitments & Contingencies

Commitments & Contingencies	9 Months Ended
	Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments & Contingencies	Note 8 – Commitments & Contingencies Operating Leases Office Space The Company pays TAG Aviation, a company owned by its Chief Executive Officer, Jarrett Gorlin (“Mr. Gorlin”) for office space that is currently being used as the Company’s principal business location plus utilities cost (see “Related-Party Transactions”) on a monthly basis. Base annual rent is $2,147 per month. Rent expense and utilities cost paid to TAG Aviation amounted to approximately $9,400 and $28,300, respectively, for the three and nine months ended September 30, 2018. Rent expense and utilities cost paid to TAG Aviation amounted to approximately $9,500 and $25,000 for the three and nine months ended September 30, 2017. On September 1, 2018, the Company extended the term of the lease agreement for the commercial building which originally commenced on August 1, 2015. The term of the new lease agreement is for two years four months commencing on September 1, 2018 and ending December 31, 2020. Base rent under the old lease agreement was $2,948 and base rent under the new agreement is $3,095. Total lease expense for the three and nine months ended September 30, 2018 was approximately $8,800 and $26,000, respectively related to this lease. Total lease expense for the three and nine months ended September 30, 2017 was approximately $8,600 and $26,000, respectively related to this lease. Future minimum lease payments under this rental agreement are approximately as follows: For the year ending: December 31, 2018 $ 9,300 December 31, 2019 37,500 December 31, 2020 38,600 $ 85,400 Equipment The Company entered into a non-cancelable 36-month operating lease agreement for equipment on March 23, 2018. The agreement is renewable at the end of the term and requires the Company to maintain comprehensive liability insurance. Total lease expense was approximately $800 and $2,500, respectively, for the three and nine months ended September 30, 2018. Total lease expense was approximately $900 and $2,900, respectively, for the three and nine months ended September 30, 2017. Future minimum lease payments under this operating lease agreement are approximately as follows: For the year ending : December 31, 2018 $ 500 December 31, 2019 1,900 December 31, 2020 1,900 December 31, 2021 500 $ 4,800 Consulting Agreements The Company has an agreement with Jesse Crowne, a Director and Co-Chairman of the Board of the Company, to provide business development consulting services for a fee of $13,333 per month. The Company incurred $39,999 and $120,000, respectively, for the three and nine months ended September 30, 2018 related to this consulting agreement, of which $13,333 was included in accounts payable at September 30, 2018. The monthly consulting fee was increased from a rate of $9,167 beginning in January 2018. The Company incurred approximately $30,000 and $85,000, respectively, for the three and nine months ended September 30, 2017 related to this consulting agreement. The Company has a consulting agreement with a sales, marketing, and distribution consultant in Latin America at a fee of $7,000 per month through December 31, 2018. The Company incurred $21,000 and $63,000, respectively, for the three and nine months ended September 30, 2018 related to this consulting agreement. The Company incurred $21,000 and $45,000, respectively, for the three and nine months ended September 30, 2017 related to this consulting agreement. The Company has consulting agreements with a varying team of sales, marketing, and distribution consultants in Europe who provide consulting services for aggregate compensation amounting to approximately €21,000 (approximately $25,000) per month. The consulting agreements, while subject to modifications, commenced at separate dates and will also terminate at separate dates through April 30, 2019. The Company incurred approximately $71,000 and $280,000, respectively, for the three and nine months ended September 30, 2018 related to these consulting agreements. The Company incurred approximately $58,000 and $131,000, respectively, for the three and nine months ended September 30, 2017 related to these consulting agreements. Generator development agreement The Company was obligated to reimburse Bovie Medical Corporation (“Bovie”) up to $295,000 for the development of the Pro-40 electrocautery generator. The Company did not incur any expenses to Bovie for the three and nine months ended September 30, 2018 under this agreement. The Company incurred approximately $3,000 and $33,000, respectively, for the three and nine months ended September 30, 2017 under this agreement. Through September 30, 2018, the Company has paid approximately $422,000 to Bovie related to this agreement. The original $295,000 agreement was a based number along the pathway of development. Additional requirements were added as the research and development process progressed and as a result certain prices increased and additional costs were added to further customize the DenerveX System. Distribution center and logistic services agreement The Company has a non-exclusive distribution center agreement with a logistics service provider in Berlin, Germany pursuant to which they manage and coordinate the DenerveX System products which the Company exports to the EU through June 2019. The Company originally paid a fixed monthly fee of €2,900 (approximately $3,500) for all accounting, customs declarations and office support, and a variable monthly fee ranging from €1,900 to €6,900 (approximately $2,300 to $8,300), based off volume of shipments, for logistics, warehousing and customer support services. Effective September 1, 2018, the fixed monthly fee was changed to €6,900 (approximately $7,900). Total expenses paid for the distribution center and logistics agreement was approximately $34,000 and $118,000, respectively, for the three and nine months ended September 30, 2018. Total expenses paid for the distribution center and logistics agreement was approximately $37,900 for the three and nine months ended September 30, 2017. Co-Development Agreement In September 2013, the Company executed a Co-Development Agreement with James R. Andrews, M.D. (“Dr. Andrews”) to further evaluate, test and advise on the development of products incorporating the use of the patented technology. In exchange for these services the Company is obligated to pay Dr. Andrews a royalty of 2% of revenues earned from applicable product sales over a period of 5 years. If Dr. Andrews is listed as inventor of any Improvement Patent on the DenerveX device during the 5-year term, he would continue to receive a 1% royalty after the 2% royalty expires for the duration of the effectiveness of the Improvement Patent. The Company incurred approximately $4,500 and $13,100, respectively, in royalty expense under the co-development agreement for the three and nine months ended September 30, 2018, all of which was included in accounts payable at September 30, 2018. The Company incurred approximately $446 in royalty expense under the co-development agreement for the three and nine months ended September 30, 2017. Patent Assignment and Contribution Agreements On February 1, 2013, the Company issued 750,108 shares of common stock to Scott Haufe, M.D. (“Dr. Haufe”) pursuant to the terms of a Contribution and Royalty Agreement dated January 31, 2013 between the Company and Dr. Haufe. This agreement provides for the Company to pay Dr. Haufe royalties equal to 1% of revenues earned from sales of any and all products derived from the use of the DenerveX technology. Royalties are payable to Dr. Haufe within 30 days after the close of each calendar quarter based on actual cash collected from sales of applicable products. The royalty period expires on September 6, 2030. The Company incurred approximately $2,300 and $6,600, respectively, in royalty expense under the Contribution and Royalty agreement for the three and nine months ended September 30, 2018, all of which was included in accounts payable at September 30, 2018. The Company incurred approximately $225 in royalty expense under the patent assignment and contribution agreement for the three and nine months ended September 30, 2017. Streamline Inc. Asset Sale The asset sale of Streamline Inc. resulted in the immediate receipt of $500,000 in cash, and a $150,000 note receivable that was due to the Company on January 1, 2018. The $150,000 note receivable represents the non-contingent portion of the receivables due from the sale. The Company received the short-term receivable on January 2, 2018. The terms of the sale also required that for each of the calendar years ending December 31, 2018 and December 31, 2019 (each such calendar year, a “Contingent Period”), a contingent payment in cash (each, a “Contingent Payment”) equal to five percent (5%) of the total net sales received by the acquiring party from the sale of “IV suspension system” products in excess of 100 units during each Contingent Period. Each such Contingent Payment is payable to the Company by the acquiring party by no later than March 31st of the subsequent year; provided, however, that the total aggregate amount of all Contingent Payments owed by the acquiring party to the Company for all Contingent Periods will not exceed $850,000. The Company is yet to receive any Contingent Payments and has no reason to expect it will receive any Contingent Payments. The Company did not incur any Streamline related expenses for the three and nine months ended September 30, 2018. The Company recorded a nominal amount in Streamline related expenses for the three and nine months ended September 30, 2017.

Short Term Liabilities

Short Term Liabilities	9 Months Ended
	Sep. 30, 2018
Debt Disclosure [Abstract]
Short Term Liabilities	Note 9 – Short Term Liabilities Finance Agreement The Company entered into a commercial insurance premium finance and security agreement in December 2017. The agreement finances the Company’s annual D&O insurance premium. Payments are due in quarterly installments of approximately $24,000 and carry an annual percentage interest rate of 5.98%. The Company had paid the yearly premium in full and had no outstanding balance as of September 30, 2018 and 2017 related to the agreement. Promissory Notes On March 26, 2018 the Company issued a promissory note to Steve Gorlin, father of Jarrett Gorlin, the Company’s CEO, for the principal amount of $200,000, plus interest, at a rate of five percent per year. The outstanding principal and all accrued but unpaid interest was originally due on May 15, 2018. The Company issued warrants to purchase an aggregate of 133,333 shares of common stock par value $.001 per share in conjunction with the promissory note to Mr. Gorlin. Each warrant has an exercise price of $0.75 and is exercisable for a period of five years commencing from the date of issuance. The Company recorded the proceeds from the promissory note and the accompanying warrants, which accrete over the period the loan is outstanding, on a relative fair basis of approximately $174,000 and $26,000, respectively. On May 15, 2018, the Company entered into a modification agreement with Steve Gorlin whereby he agreed to convert $100,000 of the outstanding promissory note into Series B Shares. (See Note 7). Additionally, the due date for the remaining $100,000 of the promissory note was extended to August 31, 2018. On August 21, 2018, the Company paid the remaining $100,000 plus unpaid accrued interest in the amount of $2,944, which was exclusive of the amortization expense recognized in connection with the accompanying warrants issued with the note, eliminating the Company’s debt obligation. (See Note 7) In conjunction with the consummation of the Streamline acquisition on March 25, 2015, the Company assumed two promissory notes for approximately $135,000 and $125,000 to the Bank of North Dakota New Venture Capital Program and North Dakota Development Fund, both outside non-related parties. Payments on both notes are due in aggregate monthly installments of approximately $5,700 and carry an interest rate of 5%. Both notes have a maturity date of August 1, 2019. The promissory notes, including interest, had outstanding balances of approximately $62,000 and $104,000 at September 30, 2018 and December 31, 2017, respectively. The Company incurred interest expense related to the promissory notes for the three and nine months ended September 30, 2018 in the amount of approximately $800 and $3,100, respectively. The Company incurred interest expense related to the promissory notes for the three and nine months ended September 30, 2017 in the amount of approximately $1,700 and $5,500, respectively. The Company had unpaid accrued interest in the amount of approximately $70,000 and $69,000 at September 30, 2018 and December 31, 2017, respectively, related to the promissory notes. Expected future payments related to the promissory notes as of September 30, 2018, are approximately as follows: For the year ending December 31, 2018 $ 17,000 December 31, 2019 45,000 $ 62,000 Convertible Debenture On January 31, 2018, the Company issued a 5% convertible debenture in exchange for $100,000. The debenture accrued interest at 5% per annum. Principal and interest were due on January 30, 2019. The debenture was convertible at the option of the holder into shares of the Company’s common stock at a conversion rate equivalent to 85% of the average closing price of the Company’s common stock for the 20 days preceding the conversion. On April 26, 2018, the convertible debenture and unpaid accrued interest was converted into an aggregate of 266,301 shares of common stock, eliminating the Company’s debt obligation (Note 7). Prior to the conversion, the Company recognized approximately $400 and $1,200, respectively, in interest expense related to the convertible debenture during the nine months ending September 30, 2018. The market value of the common stock on the date of the conversion was $0.40. This difference lead to an immaterial amount related to a beneficial conversion feature. Convertible Notes In August and September 2018, the Company entered into a securities purchase agreement with select accredited investors, whereby the Company offered up to $1,000,000 in units at a purchase price of $50,000 per unit. Each unit consists of a 12% senior secured convertible note and a three-year warrant to purchase shares of the Company’s common stock. The notes are secured by all of the assets of the Company. (See Note 7). In the offering, the Company sold an aggregate of 15 units and issued to investors an aggregate of $750,000 in principal amount of convertible notes and 1,875,000 warrants to purchase common stock, resulting in total gross proceeds of $750,000 to the Company. The convertible notes sold in the offering are convertible into an aggregate of 1,875,000 shares of common stock. The Company recorded the proceeds from the notes and the accompanying warrants, which accrete over the period the notes are outstanding, on a relative fair value basis of approximately $625,000 and $125,000, respectively. Accretion expense for the three and nine month period ending September 30, 2018 was approximately $14,000. The Company recognized $10,700 in unpaid accrued interest expense related to the notes as of September 30, 2018.

Revenue

Revenue	9 Months Ended
	Sep. 30, 2018
Revenue from Contract with Customer [Abstract]
Revenue	Note 10 – Revenue The Company sells the DenerveX System through a combination of direct sales and independent distributors in international markets. The Company recognizes revenue when title to the goods and risk of loss transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. We only record revenue when collectability is reasonably assured. Revenue recognition occurs at the time product is shipped to customers from the third-party distribution warehouse located in Berlin, Germany. Our stocking distributors, who sell the products to their customers or sub-distributors, contractually take title to the products and assume all risks of ownership at the time of shipment. Our stocking distributors are obligated to pay us the contractually agreed upon invoice price within specified terms regardless of when, if ever, they sell the products. Our direct customers do not have any contractual rights of return or exchange other than for defective product or shipping error.

Common Stock Warrants

Common Stock Warrants	9 Months Ended
	Sep. 30, 2018
Equity [Abstract]
Common Stock Warrants	Note 11 – Common Stock Warrants Fair value measurement valuation techniques, to the extent possible, should maximize the use of observable inputs and minimize the use of unobservable inputs. The Company’s fair value measurements of all warrants are designated as Level 2 since all the significant inputs are observable and quoted prices were available for the four comparative companies in an active market. A summary of the Company’s warrant issuance activity and related information for the nine months ended September 30, 2018 is as follows: Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life Outstanding at 12/31/2017 7,194,215 $ 1.74 3.40 Issued 4,705,833 (1)(2) 2.91 Outstanding and exercisable at 9/30/2018 11,900,048 $ 1.28 2.73 The fair value of all warrants issued are determined by using the Black-Scholes-Merton valuation technique and were assigned based on the relative fair value of both the common stock and the warrants issued. The inputs used in the Black-Scholes-Merton valuation technique to value each of the warrants issued at September 30, 2018 as of their respective issue dates are as follows: Event Description Date MDVX Stock Price Exercise Price of Warrant Grant Date Fair Value Life of Warrant Risk Free Rate of Return (%) Annualized Volatility Rate (%) Private placement 2/26/18 $ 0.51 $ 0.75 $ 0.20 5 years 2.60 55.91 Short-term debt 3/26/18 $ 0.53 $ 0.75 $ 0.22 5 years 2.64 56.57 Private placement 5/1/2018 $ 0.44 (1 ) $ 0.11 3 years 2.66 56.92 Debt conversion 5/15/2018 $ 0.39 (1 ) $ 0.08 3 years 2.75 57.03 Convertible notes 8/8/2018 $ 0.37 (2 ) $ 0.19 3 years 2.68 104.37 Convertible notes 9/28/2018 $ 0.40 (2 ) $ 0.21 3 years 2.88 105.07 (1) (2) The methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2018
Income Tax Disclosure [Abstract]
Income Taxes	Note 12 - Income Taxes For the period from February 1, 2013 (inception) to September 30, 2018, the Company has incurred net losses and, therefore, has no current income tax liability. The net deferred tax asset generated by these losses is fully reserved as of September 30, 2018 and December 31, 2017, since it is currently more likely than not that the benefit will not be realized in future periods. The Company is required to file federal income tax returns and state income tax returns in the states of Florida, Georgia and Minnesota. There are no uncertain tax positions at September 30, 2018 or December 31, 2017. The Company has not undergone any tax examinations since inception.

Related-Party Transactions

Related-Party Transactions	9 Months Ended
	Sep. 30, 2018
Related Party Transactions [Abstract]
Related-Party Transactions	Note 13 - Related-Party Transactions Patent Assignment and Royalty Agreements As described in Note 8, the Company has a Contribution and Royalty Agreement with Dr. Haufe, a director of the Company. The agreement provides for the Company to pay Dr. Haufe royalties equal to 1% of revenues received by the Company from sales of all products derived from the use of the DenerveX technology. The Company incurred approximately $2,300 and $6,600, respectively, in royalty expense under the Contribution and Royalty agreement for the three and nine months ended September 30, 2018, all of which was included in accounts payable at September 30, 2018. The Company incurred approximately $225 in royalty expense under the patent assignment and contribution agreement for the three and nine months ended September 30, 2017. Co-Development Agreement As described in Note 8, the Company entered into a Co-Development Agreement with Dr. Andrews, a director of the Company, in September 2013. The agreement provides for the Company to pay Dr. Andrews a royalty of 2% of the Company’s net sales earned from applicable product sales for at least 5 years from the effective date of the agreement. The Company incurred approximately $4,500 and $13,100 in royalty expense under the co-development agreement for the three and nine months ended September 30, 2018, all of which was included in accounts payable at September 30, 2018. The Company incurred approximately $446 in royalty expense under the co-development agreement for the three and nine months ended September 30, 2017. Operating Lease As described in Note 8, the Company pays TAG Aviation LLC, (“TAG”), a company owned by Mr. Gorlin, for month to month rental of office space at Dekalb-Peachtree Airport in Atlanta Georgia plus cost of utilities. Base rent payments under this arrangement is $2,147 per month. Rent expense and utilities expenses incurred by TAG Aviation amounted to approximately $9,400 and $28,300, respectively, for the three and nine months ended September 30, 2018. Approximately $6,300 was included in accounts payable as of September 30, 2018. Rent expense and utilities expenses paid to TAG Aviation amounted to approximately $9,500 and $25,000, respectively, for the three and nine months ended September 30, 2017. Consulting expense As described in Note 8, the Company paid $39,999 and $120,000, respectively, for the three and nine months ended September 30, 2018 to Jesse Crowne, a director and Co-Chairman of the Board of the Company, for business advisory services, of which $13,333 was included in accounts payable at September 30, 2018.

Research and Development

Research and Development	9 Months Ended
	Sep. 30, 2018
Research and Development [Abstract]
Research and Development	Note 14 - Research and Development Devicix Prototype Manufacturing Agreement In November 2013, the Company accepted a proposal from Devicix, a Minneapolis, Minnesota based FDA registered contract designer and developer, to develop a commercially viable prototype of its product that could be used to receive regulatory approval from the FDA and other international agencies for use on humans to relieve pain associated with Facet Joint Syndrome. Through September 30, 2018, the Company has incurred approximately $1,947,000 in fees to Devicix, of which approximately $66,000 and $7,000, respectively, was included in accounts payable as of September 30, 2018 and December 31, 2017. The development work commenced in December 2013. The total estimated cost of this work at contract signing was $960,000; however, the terms of the proposal allow either the Company or the designer and developer to cancel the development work with 10-days’ notice. The Company incurred expenses of approximately $42,000 and $98,000, respectively, for the three and nine months ended September 30, 2018. The Company incurred expenses of approximately $34,000 and $273,000, respectively, for the three and nine months ended September 30, 2017. Denervex Generator Manufacturing Agreement The DenerveX device requires a custom electrocautery generator for power. As described in Note 8, in November 2014, the Company contracted with Bovie to customize one of their existing electrocautery generators for use with DenerveX Device, and then manufacture that unit on a commercial basis once regulatory approval for the DenerveX is obtained. The Bovie agreement required a base $295,000 development fee to customize the unit, plus additional amounts if further customization was necessary beyond predetermined estimates. The Company did not incur any expenses to Bovie for the three and nine months ended September 30, 2018. The Company incurred approximately $3,000 and $33,000, respectively, for the three and nine months ended September 30, 2017. Through September 30, 2018, the Company has incurred approximately $422,000 to Bovie related to this agreement. The manufacturing agreement is complete as of September 30, 2018, and the Company does not expect to incur any more expenses related to the agreement. Nortech Manufacturing Agreement In November 2014, the Company selected Nortech Systems Inc. (“Nortech”), a Minneapolis, Minnesota based FDA registered contract manufacturer, to produce 315 DenerveX devices from the prototype supplied by Devicix for use in final development and clinical trials. The agreement with Nortech includes agreed upon per unit prices for delivery of the devices. Actual work on development of the final units began in November 2014. The Company incurred fees of approximately $0 and $107,000, respectively, to Nortech for the three and nine months ended September 30, 2018 related to the manufacturing agreement. The Company incurred fees of approximately $7,400 and $147,000, respectively, to Nortech for the three and nine months ended September 30, 2017. Through September 30, 2018, the Company has incurred expenses of approximately $997,000 to Nortech related to the manufacturing agreement.

Liquidity, Going Concern and Ma

Liquidity, Going Concern and Management's Plans	9 Months Ended
	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity, Going Concern and Management's Plans	Note 15– Liquidity, Going Concern and Management’s Plans The Company incurred net losses of approximately $3,721,000 and $4,842,000 for the nine months ended September 30, 2018 and 2017, respectively. The Company will continue to incur losses until it can sell a sufficient enough volume of the DenerveX System with margins sufficient to offset expenses. To date, the Company’s primary source of funds has been from the issuance of debt and equity. The Company will require additional cash in 2018 and is currently exploring other fundraising options. No assurances can be provided regarding the success of such efforts. Furthermore, if the Company is unable to raise sufficient financing in 2018, it could be required to undertake initiatives to conserve its capital resources, including delaying or suspending the launch of its product outside the United States and seeking FDA approval to sell its product in the United States. Delaying or suspending these initiatives would raise substantial doubt about the Company’s ability to continue as a going concern. A condition to closing the Asset Purchase Agreement as described in Note 16 is a net raise of $3,000,000 from the sale of new securities. At the time of filing, this condition had not been met. If no additional funds are raised, the Asset Purchase Agreement may not close. If that occurs, the Company will have to curtail operations, as it has no viable alternatives to this agreement. Curtailing operation would raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments to the carrying amounts of its assets or liabilities that might be necessary should the Company be unable to continue as a going concern.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2018
Subsequent Events [Abstract]
Subsequent Events	Note 16 - Subsequent Events On October 3, 2018, the Board approved the issuance of shares of common stock in lieu of cash payments due to certain directors and officers of the Company. This issuance was conditioned upon the Company signing a definitive agreement with Regenerative Medical Solutions, LLC (“RMS”). That agreement was signed on October 15, 2018, and a total of 1,168,956 shares were subsequently issued as follows: All non-employee directors were issued 35,578 shares each, for a total of 320,202 shares being issued. Executives were issued a total of 524,945 shares in lieu of cash due for 2017 bonus awards and 323,810 shares were issued to Jarrett Gorlin, former Chief Executive Officer, as severance in lieu of six months of cash salary. The 2017 bonus awards were not previously accrued as management determined it was not probable they would be paid. The board’s approval to issue shares to settle the 2017 bonus awards changed management’s probability assessment and the Company recorded the fair value of the shares issued ($210,000) as a liability at September 30, 2018. On October 9, 2018, the Company entered into an employment agreement with William E. Horne pursuant to which Mr. Horne will serve as the Company’s President and Chief Executive Officer. The employment agreement is for a term of five years subject to additional one year renewals. The employment agreement provides for an annual base salary of $650,000 provided that if he is receiving his full salary from Laser Spine Institute, his annual base salary shall be reduced to $500,000. Mr. Horne is also eligible to participate in any discretionary or incentive bonus program approved by the Company’s Compensation Committee. Mr. Horne shall also be entitled to receive incentive stock options and restricted stock awards equal to 7% of the Company’s issued and outstanding common stock, as of the closing date of the consummation of the Asset Purchase Agreement (“APA”), as discussed below, between the Company and RMS. In the event that the APA is not consummated, the employment agreement shall terminate. Mr. Jarrett Gorlin resigned as President and Chief Executive Officer upon the effectiveness of the employment agreement. On October 15, 2018, Directors Jarrett Gorlin, James R. Lawson, Randal R. Betz, John C. Thomas, Jr., James R. Andrews, Clyde A. Hennies, Jon Mogford, Scott Haufe and Jesse W. Crowne, this being all Board members except for Larry W. Papasan, tendered their resignations to Mr. Papasan, Co-Chairman of the Board. Mr. Papasan then invited newly appointed President and Chief Executive Officer, William E. Horne, to join the Board as Chairman. Mr. Horne accepted, and Mr. Papasan tendered his resignation to Mr. Horne, leaving Mr. Horne as the sole director of the Company. On October 18, 2018, the Company entered into an APA with RMS, Lung Institute LLC, RMS Lung Institute Management LLC, Cognitive Health Institute Tampa, LLC, RMS Shareholder, LLC and RMS Acquisition Corp. (“Buyer”) (collectively, the “Parties”). Pursuant to the terms of the APA, buyer shall purchase all of the assets of RMS, Cognitive Health Institute Tampa, LLC, Lung Institute LLC and RMS Lung Institute Management LLC (collectively the “Sellers”). As consideration, Buyer shall (i) deliver to Sellers (a) 583,333 shares of common stock of the Company (“Common Stock”), (b) 33,632 shares of Series C Preferred Stock of the Company (“Series C Preferred Stock”), where each share of Series C Preferred Stock will convert into 1,000 shares of Common Stock and shall combine to represent the right to convert into and acquire an aggregate of fifty-five percent (55%) of the outstanding common stock of the Company and (c) “Additional Exchange Shares” as defined in the APA; and (ii) assume certain liabilities as provided in the APA. As further consideration, the Company shall pay RMS the sum of $350,000. The close of the APA is subject to certain closing conditions as set forth in the APA.

Basis of Presentation (Policies

Basis of Presentation (Policies)	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Principles of Consolidation	principles of consolidation These unaudited condensed consolidated financial statements that present the Company’s results of operations for the three and nine months ended September 30, 2018 and 2017, and cash flows for the nine months ended September 30, 2018 and 2017, include Debride and the accounts of the Company as well as its formerly wholly-owned subsidiary, Streamline Inc. (“Streamline”). All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates In preparing the financial statements, U.S. GAAP requires disclosure regarding estimates and assumptions used by management that affect the amounts reported in financial statements and accompanying notes. The Company’s significant estimates include the deferred income tax asset and the related valuation allowance, and the fair value of its share-based payment arrangements. For those estimates that are sensitive to the outcome of future events, actual results could differ from those estimates.
Change in Accounting Estimates	Change in Accounting Estimates The Company had three years of historical stock price information available as of September 30, 2018. As such, only the Company’s historical information was solely used in calculating annualized volatility utilized in the Black-Sholes valuation method in determining the fair value of warrants issued. In prior periods, annualized volatility was calculated using the historical price of the Company’s stock price information in addition to three comparative companies in an active market.
Foreign Currency Transaction	Foreign Currency Transaction The Company’s revenues and expenses transacted in foreign currencies are recorded as they occur at exchange rates in effect at the time of each transaction. Realized gains and losses on foreign currency transactions are recorded as a component of other income or expense, net on the Company’s consolidated statements of operations. The Company recorded approximately $4,000 and $5,600, respectively, in foreign currency transaction expense for the three and nine months ended September 30, 2018. The Company did not incur any foreign currency transaction costs related to revenues and expenses transacted in foreign currencies for the three and nine months ending September 30, 2017. Foreign currency denominated monetary assets and liabilities of the Company are measured at the end of each reporting period using the exchange rate as of the balance sheet date and are recorded as a component of other income or expense, net on the Company’s consolidated statements of operations. As of September 30, 2018, the Company recorded a net translation loss of approximately $10,200 in foreign currency denominated monetary assets and liabilities. The Company did not incur any foreign currency translation costs related to foreign currency denominated monetary assets and liabilities for the three and nine months ending September 30, 2017.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements The Company considers the applicability and impact of all ASUs issued, both effective and not yet effective. In May 2014, the FASB issued ASU 2014-09, “Revenue Recognition - Revenue from Contracts with Customers” (ASU 2014-09) that requires companies to recognize revenue when a customer obtains control rather than when companies have transferred substantially all risks and rewards of a good or service. This update is effective for annual reporting periods beginning on or after December 15, 2017 and interim periods therein and requires expanded disclosures. The adoption of this standard did not have a material impact on the consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases. ASU 2016-02 is effective for public companies for annual reporting periods beginning after December 15, 2018, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. The Company is currently assessing the impact the adoption of ASU 2016-02 will have on its consolidated financial statements. In July 2017, FASB issued ASU No. 2017-11 to provide new guidance for classification and accounting of financial instruments with down round features. The update requires entities to recognize the effect of a down round feature in a freestanding equity-classified financial instrument only when it is triggered. The effect of triggering such a feature should be recognized as a dividend and a reduction to income available to common shareholders in calculating basic EPS. ASU 2017-11 is effective for public companies for annual reporting periods beginning after December 15, 2018, including interim periods therein. The Company adopted the amendments of ASU 2017-11 effective January 1, 2018.

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Sep. 30, 2018
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventories consisted of the following items as of September 30, 2018, and December 31, 2017: September 30, 2018 December 31, 2017 Split Return Electrodes $ — $ 1,868 Denervex device 71,495 111,596 Pro-40 generator 135,000 181,250 Total $ 206,495 $ 294,714

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2018
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment, net, consists of the following: Useful Life September 30, 2018 December 31, 2017 Furniture and fixtures 5 years $ 67,777 $ 67,777 Computers and software 3 years 31,738 31,738 Leasehold improvements 5 years 35,676 35,676 135,191 135,191 Less accumulated depreciation (68,640 ) (48,018 ) Total $ 66,551 $ 87,173

Equity Transactions (Tables)

Equity Transactions (Tables)	9 Months Ended
	Sep. 30, 2018
Nonmonetary Transactions [Abstract]
Summary of Stock Option Activity	The following is a summary of stock option activity at September 30, 2018: Shares Weighted Average Exercise Price Weighted Average Remaining Term (Years) Outstanding at 12/31/2017 1,314,059 $ 2.01 8.19 Forfeited (136,035 ) $ 1.69 — Outstanding at 9/30/2018 1,178,024 $ 2.04 7.45 Exercisable at 9/30/2018 1,035,200 $ 2.16 7.37

Commitments & Contingencies (Ta

Commitments & Contingencies (Tables)	9 Months Ended
	Sep. 30, 2018
Office Space [Member]
Schedule of Operating Leases	Future minimum lease payments under this rental agreement are approximately as follows: For the year ending: December 31, 2018 $ 9,300 December 31, 2019 37,500 December 31, 2020 38,600 $ 85,400
Equipment [Member]
Schedule of Operating Leases	Future minimum lease payments under this operating lease agreement are approximately as follows: For the year ending : December 31, 2018 $ 500 December 31, 2019 1,900 December 31, 2020 1,900 December 31, 2021 500 $ 4,800

Short Term Liabilities (Tables)

Short Term Liabilities (Tables)	9 Months Ended
	Sep. 30, 2018
Debt Disclosure [Abstract]
Schedule of Future Payments Related to the Promissory Notes	Expected future payments related to the promissory notes as of September 30, 2018, are approximately as follows: For the year ending December 31, 2018 $ 17,000 December 31, 2019 45,000 $ 62,000

Common Stock Warrants (Tables)

Common Stock Warrants (Tables)	9 Months Ended
	Sep. 30, 2018
Equity [Abstract]
Summary of Warrant Activity	A summary of the Company’s warrant issuance activity and related information for the nine months ended September 30, 2018 is as follows: Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life Outstanding at 12/31/2017 7,194,215 $ 1.74 3.40 Issued 4,705,833 (1)(2) 2.91 Outstanding and exercisable at 9/30/2018 11,900,048 $ 1.28 2.73
Schedule of Assumptions for Warrants	The inputs used in the Black-Scholes-Merton valuation technique to value each of the warrants issued at September 30, 2018 as of their respective issue dates are as follows: Event Description Date MDVX Stock Price Exercise Price of Warrant Grant Date Fair Value Life of Warrant Risk Free Rate of Return (%) Annualized Volatility Rate (%) Private placement 2/26/18 $ 0.51 $ 0.75 $ 0.20 5 years 2.60 55.91 Short-term debt 3/26/18 $ 0.53 $ 0.75 $ 0.22 5 years 2.64 56.57 Private placement 5/1/2018 $ 0.44 (1 ) $ 0.11 3 years 2.66 56.92 Debt conversion 5/15/2018 $ 0.39 (1 ) $ 0.08 3 years 2.75 57.03 Convertible notes 8/8/2018 $ 0.37 (2 ) $ 0.19 3 years 2.68 104.37 Convertible notes 9/28/2018 $ 0.40 (2 ) $ 0.21 3 years 2.88 105.07

Description of the Company (Det

Description of the Company (Details Narrative)	9 Months Ended
	Sep. 30, 2018
State of incorporation	Nevada
Date of incorporation	Jul. 30, 2013
Debride Inc. [Member]
State of incorporation	Florida
Date of incorporation	Oct. 1, 2012

Basis of Presentation (Details

Basis of Presentation (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Accounting Policies [Abstract]
Foreign currency translation expense	$ 4,000		$ 5,600
Unrealized foreign currency translation	$ 10,200		$ 10,200

Inventory - Schedule of Invento

Inventory - Schedule of Inventory (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Inventory	$ 206,495	$ 294,714
Split Return Electrodes [Member]
Inventory		1,868
Denervex Device [Member]
Inventory	71,495	111,596
Pro-40 Generator [Member]
Inventory	$ 135,000	$ 181,250

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 6,728	$ 7,109	$ 20,622	$ 20,000

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	9 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Property and equipment	$ 135,191	$ 135,191
Less accumulated depreciation	(68,640)	(48,018)
Property and Equipment, net	66,551	87,173
Furniture and Fixtures [Member]
Property and equipment	$ 67,777	67,777
Useful Life	5 years
Computers and Software [Member]
Property and equipment	$ 31,738	31,738
Useful Life	3 years
Leasehold Improvements [Member]
Property and equipment	$ 35,676	$ 35,676
Useful Life	5 years

Equity Transactions (Details Na

Equity Transactions (Details Narrative) - USD ($)	May 15, 2018	May 01, 2018	Apr. 26, 2018	Mar. 30, 2018	Feb. 26, 2018	Sep. 30, 2018	Aug. 31, 2018	Aug. 31, 2017	Jan. 31, 2017	Nov. 30, 2016	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Aug. 21, 2018	Dec. 31, 2017	Jan. 17, 2017
Proceeds from issuance of common stock										$ 240,000			$ 901,291	$ 3,838,671
Number of shares issued							75,000		173,911
Shares issued price per share							$ 0.32		$ 1.38								$ 1.16
Number of common stock issued, value							$ 24,000
Non vested options outstanding						142,825					142,825		142,825
Unrecognized stock-based compensation						$ 53,000					$ 53,000		$ 53,000
Weighted average period													1 year 4 months 20 days
Warrant term	3 years
Warrant, exercise price	$ 0.75
Legal expenses													$ 13,500
Proceeds from issuance of warrants													$ 238,855	1,248,575
Common stock, par value				$ 0.001		$ 0.001					$ 0.001		$ 0.001			$ 0.001
Unpaid accrued interest															$ 100,000
Debt obligations															$ 2,944
Series B [Member]
Number of warrants issued to purchase common shares	250,000
Dividend rate	5.00%
Beneficial conversion feature of preferred stock	$ 14,000
Debt conversion, shares	1,000
Debt conversion of convertible debt	$ 100,000
Debt obligations	200,000
Promissory Note [Member]
Debt conversion of convertible debt	$ 200,000
Common Stock [Member]
Number of common stock shares issued for services													74,990
Conversion of stock shares converted	250		266,301
Common stock conversion price, per share	$ 0.40
5% Convertible Debenture [Member]
Common stock conversion price, per share			$ 0.38			$ 0.40					$ 0.40		$ 0.40
Conversion of common stock, percentage			85.00%
Debt conversion, shares			266,301
Debt conversion of convertible debt			$ 100,000
Series B Convertible Preferred Stock [Member]
Debt conversion of convertible debt	$ 100,000
Series A Preferred Stock [Member]
Number of common stock shares issued for services
Conversion of stock shares converted				12,740
Securities Purchase Agreement [Member] | Accredited Investors [Member]
Proceeds from issuance of common stock		$ 100,000
Common stock issued percentage						100.00%	100.00%
Number of common stock shares sold					770,000								8.25
Number of warrants issued to purchase common shares					385,000	2,062,500					2,062,500		2,062,500
Proceeds from issuance of private placement					$ 308,000
Warrant term		3 years			5 years	3 years	3 years
Warrant, exercise price		$ 0.75			$ 0.75	$ 0.75	$ 0.75				$ 0.75		$ 0.75
Allocation of warrants					52,003
Legal expenses													$ 5,000
Number of common stock shares sold, value		$ 1,000,000				$ 1,000,000	$ 1,000,000
Common stock conversion price, per share						$ 0.40	$ 0.40				0.40		$ 0.40
Proceeds from issuance of warrants													$ 825,000
Net cash received from offering													$ 820,000
Common stock, par value						0.001	0.001				0.001		$ 0.001
Sale of stock price per share						$ 50,000	$ 50,000				$ 50,000		$ 50,000
Conversion of common stock, percentage						12.00%	12.00%
Purchase price of common stock percentage						90.00%	90.00%
Accretion expense											$ 14,000		$ 14,000
Unpaid accrued interest						$ 10,700					$ 10,700		$ 10,700
Securities Purchase Agreement [Member] | Accredited Investors [Member] | Series B Convertible Preferred Stock [Member]
Number of common stock shares sold		1,000											8,250
Dividend rate		5.00%
Conversion of stock shares converted													2,062,500
Beneficial conversion feature of preferred stock													$ 246,000
Securities Purchase Agreement [Member] | Accredited Investors [Member] | Common Stock [Member]
Number of warrants issued to purchase common shares		250,000
Warrant, exercise price		$ 0.001
Conversion of stock shares converted		250
Common stock conversion price, per share		$ 0.40
Market value of common stock		$ 0.44
Securities Purchase Agreement [Member] | Investors [Member]
Number of common stock shares sold													15
Number of warrants issued to purchase common shares						1,875,000					1,875,000		1,875,000
Number of common stock shares sold, value													$ 750,000
Proceeds from issuance of warrants													$ 750,000
Sale of stock price per share						$ 50,000					$ 50,000		$ 50,000
Debt conversion, shares													1,875,000
Fair value of warrants													$ 505,000
Proceeds from notes													245,000
Accretion expense													28,400
Unpaid accrued interest						$ 10,700					$ 10,700		10,700
May 1, 2018 Securities Purchase Agreement [Member]
Debt conversion of convertible debt	$ 100,000
2013 Stock Option Incentive Plan [Member]
Compensation expense											$ 22,000	$ 111,000	$ 107,000	$ 612,000
1 Year [Member]
Common stock issued percentage								25.00%
2 Years [Member]
Common stock issued percentage								50.00%
Restricted Common Stock [Member]
Conversion of stock shares converted				1,274,000
Board of Directors and Certain Consultant [Member]
Number of common stock shares issued for services								300,000
Common stock issued percentage								25.00%

Equity Transactions - Summary o

Equity Transactions - Summary of Stock Option Activity (Details)	9 Months Ended
	Sep. 30, 2018$ / sharesshares
Equity [Abstract]
Shares, Outstanding, Beginning | shares	1,314,059
Shares, Forfeited | shares	(136,035)
Shares, Outstanding, Ending | shares	1,178,024
Shares, Exercisable | shares	1,035,200
Weighted Average Exercise Price, Outstanding, Beginning | $ / shares	$ 2.01
Weighted Average Exercise Price, Forfeited | $ / shares	1.69
Weighted Average Exercise Price, Outstanding, Ending | $ / shares	2.04
Weighted Average Exercise Price, Outstanding, Exercisable | $ / shares	$ 2.16
Weighted Average Remaining Term (Years), Outstanding, Beginning	8 years 2 months 8 days
Weighted Average Remaining Term (Years), Forfeited	0 years
Weighted Average Remaining Term (Years), Outstanding, Ending	7 years 5 months 12 days
Weighted Average Remaining Term (Years), Exercisable	7 years 4 months 13 days

Commitments & Contingencies (De

Commitments & Contingencies (Details Narrative)	Sep. 02, 2018USD ($)	Sep. 02, 2018EUR (€)	Jan. 02, 2018USD ($)	Feb. 01, 2013shares	Aug. 31, 2018shares	Jan. 31, 2018USD ($)	Jan. 31, 2017shares	Sep. 30, 2013	Sep. 30, 2018USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2018EUR (€)	Sep. 30, 2017USD ($)	Dec. 31, 2017USD ($)
Base rent									$ 2,948		$ 2,948
Lease expense									8,800	$ 8,600	26,000		$ 26,000
Accounts payable									688,958		688,958			$ 196,171
Monthly fees									34,000	37,900	118,000		37,900
Number of common stock shares issued | shares					75,000		173,911
Sales, Marketing, and Distribution Consultant One [Member]
Payments for consulting services									71,000	58,000	280,000		131,000
Old Lease Agreement [Member]
Base rent									2,948
New Lease Agreement [Member]
Base rent									$ 3,095
Agreement, term									2 years
Non-cancellable 36 Month Operating Lease Agreement [Member]
Lease expense									$ 800	900	2,500		2,900
Consulting Agreement [Member]
Consulting fees											13,333
Payments for consulting services									39,999	30,000	120,000		85,000
Accounts payable									13,333		13,333
Increase in consulting fees						$ 9,167
Consulting Agreement [Member] | Sales, Marketing, and Distribution Consultant [Member]
Payments for consulting services									21,000	21,000	63,000		45,000
Consulting Agreement [Member] | Sales, Marketing, and Distribution Consultant [Member] | Through December 31, 2018 [Member]
Payments for consulting services											7,000
Consulting Agreement [Member] | Sales, Marketing, and Distribution Consultant One [Member]
Payments for consulting services											$ 25,000
Termination date											Apr. 30, 2019	Apr. 30, 2019
Consulting Agreement [Member] | Sales, Marketing, and Distribution Consultant One [Member] | EURO [Member]
Payments for consulting services | €												€ 21,000
Generator Development Agreement [Member]
Payment to bovie											$ 422,000
Generator Development Agreement [Member] | Pro-40 Electrocautery Generator [Member]
Payment to bovie										3,000			33,000
Generator Development Agreement [Member] | Pro-40 Electrocautery Generator [Member] | Maximum [Member]
Payment to bovie											295,000
Distribution Center and Logistic Services Agreement [Member]
Monthly fees	$ 7,900										3,500
Distribution Center and Logistic Services Agreement [Member] | Maximum [Member]
Monthly fees											8,300
Distribution Center and Logistic Services Agreement [Member] | Minimum [Member]
Monthly fees											2,300
Distribution Center and Logistic Services Agreement [Member] | EURO [Member]
Monthly fees | €		€ 6,900										2,900
Distribution Center and Logistic Services Agreement [Member] | EURO [Member] | Maximum [Member]
Monthly fees | €												6,900
Distribution Center and Logistic Services Agreement [Member] | EURO [Member] | Minimum [Member]
Monthly fees | €												€ 1,900
Co-Development Agreement [Member]
Agreement, description								In exchange for these services the Company is obligated to pay Dr. Andrews a royalty of 2% of revenues earned from applicable product sales over a period of 5 years. If Dr. Andrews is listed as inventor of any Improvement Patent on the DenerveX device during the 5-year term, he would continue to receive a 1% royalty after the 2% royalty expires for the duration of the effectiveness of the Improvement Patent.
Royalty expense									4,500		13,100
Patent Assignment and Contribution Agreement [Member] | Scott Haufe [Member]
Agreement, description				This agreement provides for the Company to pay Dr. Haufe royalties equal to 1% of revenues earned from sales of any and all products derived from the use of the DenerveX technology. Royalties are payable to Dr. Haufe within 30 days after the close of each calendar quarter based on actual cash collected from sales of applicable products.
Royalty expense									2,300	225	6,600		225
Number of common stock shares issued | shares				750,108
Royalty expiration				Sep. 6, 2030
TAG Aviation LLC [Member]
Base rent									$ 9,400	$ 9,500	28,300		$ 25,000
Streamline Inc. [Member]
Proceeds from sale of assets			$ 500,000
Contingent description			The terms of the sale also required that for each of the calendar years ending December 31, 2018 and December 31, 2019 (each such calendar year, a "Contingent Period"), a contingent payment in cash (each, a "Contingent Payment") equal to five percent (5%) of the total net sales received by the acquiring party from the sale of "IV suspension system" products in excess of 100 units during each Contingent Period.
Contingent payments			$ 850,000
Streamline Inc. [Member] | Notes Receivable [Member]
Proceeds from sale of assets			$ 150,000
Operating Leases [Member]
Base rent											$ 2,147

Commitments & Contingencies - S

Commitments & Contingencies - Schedule of Operating Leases (Details)	Sep. 30, 2018USD ($)
Office Space [Member]
December 31, 2018	$ 9,300
December 31, 2019	37,500
December 31, 2020	38,600
Total	85,400
Equipment [Member]
December 31, 2018	500
December 31, 2019	1,900
December 31, 2020	1,900
December 31, 2021	500
Total	$ 4,800

Short Term Liabilities (Details

Short Term Liabilities (Details Narrative) - USD ($)	Aug. 21, 2018	May 15, 2018	May 01, 2018	Apr. 26, 2018	Mar. 26, 2018	Feb. 26, 2018	Jan. 31, 2018	Mar. 25, 2015	Sep. 30, 2018	Aug. 31, 2018	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Mar. 30, 2018	Dec. 31, 2017
Promissory note face amount									$ 62,000		$ 62,000		$ 62,000			$ 104,000
Common stock, par value									$ 0.001		$ 0.001		$ 0.001		$ 0.001	$ 0.001
Warrant, exercise price		$ 0.75
Warrant term		3 years
Proceeds from debt													$ 74,354
Conversion of stock shares converted amount													101,194	718,079
Repayment of debt													215,730	112,342
Unpaid accrued interest									$ 70,000		$ 70,000		70,000			$ 69,000
Proceeds from warrants													238,855	1,248,575
Unpaid accrued interest	$ 100,000
Common Stock [Member]
Conversion of stock shares converted		250		266,301
Market value of common stock		$ 0.40
5% Convertible Debenture [Member]
Debt instrument interest rate							5.00%
Debt instrument maturity date							Jan. 30, 2019
Proceeds from debt							$ 100,000
Debt conversion percentage							85.00%
Convertible Debenture [Member]
Interest expense											$ 400		$ 1,200
Market value of common stock									$ 0.40		$ 0.40		$ 0.40
Steve Gorlin [Member] | Series B Convertible Preferred Stock [Member]
Promissory note face amount		$ 100,000
Debt instrument maturity date		Aug. 31, 2018
Conversion of stock shares converted amount		$ 100,000
Repayment of debt	100,000
Unpaid accrued interest	$ 2,944
Promissory Note [Member] | Steve Gorlin [Member]
Promissory note face amount					$ 200,000
Debt instrument interest rate					5.00%
Debt instrument maturity date					May 15, 2018
Warrants to purchase shares of common stock					133,333
Common stock, par value					$ 0.001
Warrant, exercise price					$ 0.75
Warrant term					5 years
Proceeds from debt											$ 174,000		$ 26,000
Promissory Note One [Member]
Promissory note face amount								$ 135,000
Debt instrument interest rate								5.00%
Debt instrument maturity date								Aug. 1, 2019
Monthly installment amount								$ 5,700
Interest expense											800	$ 1,700	3,100	$ 5,500
Promissory Note Two [Member]
Promissory note face amount								$ 125,000
Debt instrument interest rate								5.00%
Debt instrument maturity date								Aug. 1, 2019
Monthly installment amount								$ 5,700
Finance Agreement [Member]
Insurance premium finance payments due									$ 24,000		$ 24,000		$ 24,000
Insurance premium finance annual percentage									5.98%		5.98%		5.98%
Securities Purchase Agreement [Member] | Accredited Investors [Member]
Warrants to purchase shares of common stock									1,875,000		1,875,000		1,875,000
Common stock, par value									$ 0.001	$ 0.001	$ 0.001		$ 0.001
Warrant, exercise price			$ 0.75			$ 0.75			$ 0.75	$ 0.75	$ 0.75		$ 0.75
Warrant term			3 years			5 years			3 years	3 years
Unpaid accrued interest									$ 10,700		$ 10,700		$ 10,700
Market value of common stock									$ 0.40	$ 0.40	$ 0.40		$ 0.40
Number of common stock shares sold, value			$ 1,000,000						$ 1,000,000	$ 1,000,000
Sale of stock price per share									$ 50,000	$ 50,000	$ 50,000		$ 50,000
Conversion of common stock, percentage									12.00%	12.00%
Number of units sold						770,000							8.25
Proceeds from warrants													$ 825,000
Accretion expense											$ 14,000		14,000
Unpaid accrued interest									$ 10,700		$ 10,700		10,700
Securities Purchase Agreement [Member] | Investors [Member]
Number of common stock shares sold, value													$ 750,000
Sale of stock price per share									$ 50,000		$ 50,000		$ 50,000
Number of units sold													15
Number of shares issued on conversion													1,875,000
Proceeds from warrants													$ 750,000
Fair value of warrants													505,000
Proceeds from the notes													125,000
Accretion expense													28,400
Unpaid accrued interest									$ 10,700		$ 10,700		$ 10,700
Securities Purchase Agreement [Member] | Series B Convertible Preferred Stock [Member] | Accredited Investors [Member]
Conversion of stock shares converted													2,062,500
Number of units sold			1,000										8,250

Short Term Liabilities - Schedu

Short Term Liabilities - Schedule of Future Payments Related to the Promissory Notes (Details)	Sep. 30, 2018USD ($)
Debt Disclosure [Abstract]
December 31, 2018	$ 17,000
December 31, 2019	45,000
Total	$ 62,000

Common Stock Warrants - Summary

Common Stock Warrants - Summary of Warrant Activity (Details)	9 Months Ended
	Sep. 30, 2018$ / sharesshares
Equity [Abstract]
Shares, Outstanding, Beginning	7,194,215
Shares, Issued	4,705,833
Shares, Outstanding, Ending	11,900,048
Shares, Exercisable, Ending	11,900,048
Weighted Average Exercise Price, Outstanding, Beginning | $ / shares	$ 1.74
Weighted Average Exercise Price, Issued | $ / shares
Weighted Average Exercise Price, Outstanding, Ending | $ / shares	$ 1.28
Weighted Average Exercise Price, Exercisable, Ending	1.28
Weighted Average Remaining Contractual Life, Outstanding, Beginning	3 years 4 months 24 days
Weighted Average Remaining Contractual Life, Issued	2 years 10 months 28 days
Weighted Average Remaining Contractual Life, Outstanding, Ending	2 years 8 months 23 days
Weighted Average Remaining Contractual Life, Exercisable, Ending	2 years 8 months 23 days

Common Stock Warrants - Schedul

Common Stock Warrants - Schedule of Assumptions for Warrants (Details) - $ / shares	9 Months Ended
	Sep. 30, 2018	May 15, 2018
Exercise Price of Warrant		$ 0.75
Private Placement 2/26/18 [Member]
MDVX Stock Price	$ 0.51
Exercise Price of Warrant	0.75
Private Placement 2/26/18 [Member] | Measurement Input, Exercise Price [Member]
Fair value assumptions, measurement input, exercise price	$ 0.20
Private Placement 2/26/18 [Member] | Measurement Input, Expected Term [Member]
Fair value assumptions, measurement input, term	5 years
Private Placement 2/26/18 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair value assumptions, measurement input, percentage	2.60%
Private Placement 2/26/18 [Member] | Measurement Input, Price Volatility [Member]
Fair value assumptions, measurement input, percentage	55.91%
Short-term Debt 3/26/18 [Member]
MDVX Stock Price	$ 0.53
Exercise Price of Warrant	0.75
Short-term Debt 3/26/18 [Member] | Measurement Input, Exercise Price [Member]
Fair value assumptions, measurement input, exercise price	$ 0.22
Short-term Debt 3/26/18 [Member] | Measurement Input, Expected Term [Member]
Fair value assumptions, measurement input, term	5 years
Short-term Debt 3/26/18 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair value assumptions, measurement input, percentage	2.64%
Short-term Debt 3/26/18 [Member] | Measurement Input, Price Volatility [Member]
Fair value assumptions, measurement input, percentage	56.57%
Private Placement 5/1/18 [Member]
MDVX Stock Price	$ 0.44
Exercise Price of Warrant	0.75
Private Placement 5/1/18 [Member] | Measurement Input, Exercise Price [Member]
Fair value assumptions, measurement input, exercise price	$ 0.11
Private Placement 5/1/18 [Member] | Measurement Input, Expected Term [Member]
Fair value assumptions, measurement input, term	3 years
Private Placement 5/1/18 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair value assumptions, measurement input, percentage	2.66%
Private Placement 5/1/18 [Member] | Measurement Input, Price Volatility [Member]
Fair value assumptions, measurement input, percentage	56.92%
Short-term Debt 5/15/18 [Member]
MDVX Stock Price	$ 0.39
Exercise Price of Warrant	0.75
Short-term Debt 5/15/18 [Member] | Measurement Input, Exercise Price [Member]
Fair value assumptions, measurement input, exercise price	$ 0.08
Short-term Debt 5/15/18 [Member] | Measurement Input, Expected Term [Member]
Fair value assumptions, measurement input, term	3 years
Short-term Debt 5/15/18 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair value assumptions, measurement input, percentage	2.75%
Short-term Debt 5/15/18 [Member] | Measurement Input, Price Volatility [Member]
Fair value assumptions, measurement input, percentage	57.03%
Convertible Notes 8/8/2018 [Member]
MDVX Stock Price	$ 0.37
Exercise Price of Warrant	0.75
Convertible Notes 8/8/2018 [Member] | Measurement Input, Exercise Price [Member]
Fair value assumptions, measurement input, exercise price	$ 0.19
Convertible Notes 8/8/2018 [Member] | Measurement Input, Expected Term [Member]
Fair value assumptions, measurement input, term	3 years
Convertible Notes 8/8/2018 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair value assumptions, measurement input, percentage	2.68%
Convertible Notes 8/8/2018 [Member] | Measurement Input, Price Volatility [Member]
Fair value assumptions, measurement input, percentage	104.37%
Convertible Notes 9/28/2018 [Member]
MDVX Stock Price	$ 0.40
Exercise Price of Warrant	0.75
Convertible Notes 9/28/2018 [Member] | Measurement Input, Exercise Price [Member]
Fair value assumptions, measurement input, exercise price	$ 0.21
Convertible Notes 9/28/2018 [Member] | Measurement Input, Expected Term [Member]
Fair value assumptions, measurement input, term	3 years
Convertible Notes 9/28/2018 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair value assumptions, measurement input, percentage	2.88%
Convertible Notes 9/28/2018 [Member] | Measurement Input, Price Volatility [Member]
Fair value assumptions, measurement input, percentage	105.07%

Related-Party Transactions (Det

Related-Party Transactions (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Rent expense		$ 2,948		$ 2,948
Jesse Crowne [Member]
Accounts payable		13,333		13,333
Consulting expenses		39,999		120,000
TAG Aviation LLC [Member]
Rent expense		9,400	$ 9,500	28,300	$ 25,000
Accounts payable		6,300		6,300
Mr. Gorlin [Member] | TAG Aviation LLC [Member]
Rent expense				$ 2,147
Patent Assignment and Royalty Agreement [Member] | Dr. Haufe [Member]
Agreement, description				The agreement provides for the Company to pay Dr. Haufe royalties equal to 1% of revenues received by the Company from sales of all products derived from the use of the DenerveX technology.
Royalty expense		2,300	225	$ 6,600	$ 225
Co-Development Agreement [Member]
Agreement, description	In exchange for these services the Company is obligated to pay Dr. Andrews a royalty of 2% of revenues earned from applicable product sales over a period of 5 years. If Dr. Andrews is listed as inventor of any Improvement Patent on the DenerveX device during the 5-year term, he would continue to receive a 1% royalty after the 2% royalty expires for the duration of the effectiveness of the Improvement Patent.
Royalty expense		4,500		$ 13,100
Co-Development Agreement [Member] | Dr. Andrews [Member]
Agreement, description				The agreement provides for the Company to pay Dr. Andrews a royalty of 2% of the Company's net sales earned from applicable product sales for at least 5 years from the effective date of the agreement.
Royalty expense		$ 4,500	$ 446	$ 13,100	$ 446

Research and Development (Detai

Research and Development (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Contract cost			$ 960,000
Research and Development expenses	$ 46,219	$ 70,151	201,529	$ 461,924
Devicix Prototype Manufacturing Agreement [Member]
Development fees			1,947,000
Accounts payable	66,000	7,000	66,000	7,000
Research and Development expenses	42,000	34,000	98,000	273,000
Denervex Generator Manufacturing Agreement [Member]
Development fees			295,000
Payment to administrative fee		3,000		33,000
Denervex Generator Manufacturing Agreement [Member] | Bovie [Member]
Payment to administrative fee			422,000
Nortech Manufacturing Agreement [Member]
Development fees	$ 0		107,000
Research and Development expenses			$ 997,000
Nortech Manufacturing Agreement [Member] | Nortech [Member]
Payment to administrative fee		$ 7,400		$ 147,000

Liquidity, Going Concern and _2

Liquidity, Going Concern and Management's Plans (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ 1,172,297	$ 1,367,354	$ 3,511,980	$ 4,841,591

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Oct. 18, 2018	Oct. 09, 2018	Oct. 03, 2018	May 15, 2018	Apr. 26, 2018	Aug. 31, 2018	Jan. 31, 2017
Number of shares issued						75,000	173,911
Common Stock [Member]
Number of stock converted				250	266,301
Subsequent Event [Member]
Number of shares issued			1,090,412
Subsequent Event [Member] | Asset Purchase Agreement [Member]
Share conversion description	Each share of Series C Preferred Stock will convert into 1,000 shares of Common Stock and shall combine to represent the right to convert into and acquire an aggregate of fifty-five percent (55%) of the outstanding common stock of the Company
Number of stock converted	1,000
Consideration paid	$ 350,000
Subsequent Event [Member] | Asset Purchase Agreement [Member] | Series C Preferred Stock [Member]
Number of shares issued for asset purchase	33,632
Subsequent Event [Member] | Asset Purchase Agreement [Member] | Common Stock [Member]
Number of shares issued for asset purchase	583,333
Subsequent Event [Member] | Non-employee Directors [Member]
Number of shares issued			320,202
Number of shares issued for each directors			35,578
Subsequent Event [Member] | Executives [Member]
Number of shares issued			524,945
Subsequent Event [Member] | Jarrett Gorlin [Member]
Number of shares issued			323,810
Subsequent Event [Member] | William E. Horne [Member] | Employment Agreement [Member]
Term of agreement		5 years
Salary description		The employment agreement provides for an annual base salary of $650,000 provided that if he is receiving his full salary from Laser Spine Institute, his annual base salary shall be reduced to $500,000.
Annual base salary		$ 650,000
Common stock percentage		7.00%